Epigenetics and Immunotherapy: New Perspective for Breaking Chronic Viral Infection

Jiabin Yan

Center for life science, Program in cellular and molecular medicine, Boston Children's Hospital; 3 Blackfan Circle, Boston MA 0211, USA

Corresponding author: Jiabin Yan, Center for life science, Program in cellular and molecular medicine, Boston Children's Hospital; 3 Blackfan Circle, Boston MA 0211, USA; Tel: 617-713-8208; E-mail: bijyan2004@gmail.com; Jiabin_Yan@childrens.harvard.edu

Received date: Nov 1, 2015; Accepted date: Dec, 2015; Published date: Dec 28, 2015

Copyright: © 2015 Yan J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Chronic or persistent viral infections, like HBV, HCV and HIV, are still a challenge for human health. More importantly, most human chronic viral infection will result in cancer, the top leading cause of death. So far antiviral drugs and immunotherapy have limited therapeutic effects on patients. New potential mechanisms of chronic viral infections are needed to explore before new effective therapeutic strategies can be put into use. Epigenetic alterations are an important hallmark of cancer. Recent studies indicate that chronic viral infections also induce epigenetic changes in the host. This review will try to summarize some of the most recent studies in these fields and explore a new strategy to break chronic viral infection by combining epigenetic therapy and immunotherapy.

Keywords: Epigenetics; Immunotherapy; Chronic viral infection; DNA methylation; Histone modification

Introduction

Epigenetics refers to heritable and potentially reversible changes in gene expression that do not change the primary sequence of genomic DNA [1]. The most extensively studied epigenetic modifications are DNA methylation and histone posttranslational modifications [2]. It is well-known that there are eight hallmarks of cancer [3]. Recently, epigenetic alterations are considered as a new hallmark of cancer [4-6]. However, more and more studies have indicated that epigenetic modifications are also associated with chronic viral infections, including HIV [7], HBV [8] and HCV [9]. In the present review, I will give a brief summary of chronic viral infection and further discuss a new strategy to break chronic viral infection by combining immunotherapy and epigenetic modifications.

Chronic Viral Infection

Most viral infections are resolved due to clearance of viruses by the host immune system. However, some viruses can establish persistent infections (in many cases initiated by an acute infection) through adoption of sophisticated relationships with their hosts and manipulation of a wide array of cellular mechanisms for their own advantage [10]. The so-called chronic viral infections are largely due to the failure of immediate viral clearance, where the host's immune system is not appropriately induced or infected viruses modify the relevant immune signaling and cellular apoptotic pathways [10].

Both DNA viruses (like HBV and HPV) and RNA viruses (like HCV and HIV) can induce chronic infections in humans [11]. Persistent viral infections are also found in nonhuman primates and mice, like simian immunodeficiency virus (SIV) and lymphocytic choriomeningitis virus (LCMV), respectively. Both SIV and LCMV infections are good models to study the mechanisms of chronic viral infection. Several mechanisms have been reported to regulate immune responses during chronic viral infection. Upregulation of inhibitory receptors on exhausted CD8 T cells is an important one. These inhibitory receptors include PD-, CTLA, LAG, etc [11].

Chronic viral infection is a challenging health problem for humans. Now it is clear that persistent viral infection will result in cancer development, like HPV and HBV [12]. It is estimated that chronic HBV infection accounts for more than 80% of HCC [13]. As for RNA viruses, HIV predisposes to the development of non-Hodgkin's lymphoma, squamous cell carcinomas, and Kaposi's sarcoma while the human T-cell lymphoma virus causes adult T-cell leukemia [14]. Viruses that induce cancer are also called tumor viruses. Tumor viruses induce malignant transformation in host through several strategies [15], including apoptosis inhibition, cell cycle deregulation, blocking of senescence, induction of genetic instability and promotion of angiogenesis.

Epigenetics in Viral Infection

Epigenetic regulation in viral infection includes two different meanings. One is that tumor viruses themselves undergo epigenetic changes; the other is that viruses cause epigenetic changes in host. Epigenetics play an important role in control of tumor viruses' life cycle and the transformation of a normal cell to a cancer cell [16]. One example is silenced HIV genomes, which is a major obstacle for a curative treatment of AIDS patients [17]. The two extensively studied epigenetics are DNA methylation and histone modification. Okamoto et al., [18] reported that HBV and HCV infection induced aberrant DNA methylation in mice with humanized livers. Lusic et al., [19] found that histone acetylation was involved in regulating of HIV-1 gene expression and factor recruitment at the LTR promoter. In addition, DNA methylation is involved in controlling viral genome of HPV [20]. Repression of tumor suppressor genes by inducing promoter hypermethylation is an important reason for carcinogenesis [22]. More interestingly, it is found that HPV16 can epigenetically silence the interferon-κ gene [23], which indicates that chronic viral infection is able to suppress the host's innate immunity. Actually chronic viral infections also influence adaptive immune responses by epigenetic strategy. Youngblood et al., [2,25] reported that decreased
DNA methylation of the PD1 locus in CD8+ T cells happened in both chronic LCMV and HIV infections. Taken together, epigenetic control of tumor viruses' life cycle is popular [26,27]. In addition, chronic viral infections are able to modify both host's innate and adaptive immunity by epigenetic strategy. These indicate that epigenetic therapy may be useful for interrupting and breaking chronic viral infection.

**Immunotherapy for Chronic Viral Infection**

Immunotherapy is a therapeutic method to boost the host's innate and adaptive immune responses to fight infectious diseases and cancer. As antiviral drugs are expensive and showing viral resistance and drug toxicity, immunotherapy is becoming a promising strategy to conquer chronic viral infection [28]. One strong evidence of HBV immunotherapy is that resolution of chronic HBV infection can be achieved by bone marrow transplantation from an immune donor [29]. Using a dually functional vector containing both an immunostimulating single-stranded RNA (ssRNA) and an HBx-silencing short hairpin RNA (shRNA), Lan et al., [30] reported that HBV-impaired hepatocyte-intrinsic innate immunity could be recovered in a mouse model. They further showed that the recovered innate immunity could overcome systemic adaptive immunotolerance in an IFN-α- and TLR7- dependent manner. Moody et al., [31] found that combination of TLR7/8 and TLR9 agonists was able to elicit the highest titers of binding, neutralizing, and antibody-dependent cellular cytotoxicity-mediating antibodies against HIV-1 envelope gp140. As the enhanced immune response was associated with the release of CXCL10 (IP-10), it indicated that the TLR adjuvant formulation may have optimally stimulated innate and adaptive immunity to elicit high titers of antibodies.

There are different types of immunotherapy for chronic viral infection, including cytokine delivery [32], therapeutic vaccines and blocking antibodies targeting co-inhibitory receptors such as PD-1 [33]. Therapeutic vaccines are one major immunotherapy strategy, where a variety of platforms and approaches including DNA, viral vectors, dendritic cells and peptides are tested, together with some adjuvants and immune modulators [34]. It is well-accepted that combination therapy will have better effect. One example is that combining antagonists of IL-10R or PD-1 with a therapeutic vaccine strengthened the effects in a murine model of persistent lymphocytic choriomeningitis virus (LCMV) infection [35]. Table 1 lists some of the representative studies for immunotherapy on chronic virus infections.

| Virus  | Reagent                        | References           |
|--------|--------------------------------|----------------------|
| HIV    | 3BNC117                        | Caskey et al. [36]   |
| HBV    | IFN-α                          | Lucifora et al. [37] |
| HCV    | Adenoviral vaccine             | Barnes et al. [38]   |
| LCMV   | PD-L1 blockade                 | Penaloza-MacMaster et al. [35] |

Table 1: Immunotherapy for chronic viral infections.

**Epigenetic therapy for Chronic Viral Infection**

During epigenetic therapy, two most studied enzymes are DNA methyl transferase (DNMT) and histone deacetyase (HDAC). Accordingly, the best characterized epigenetic drugs are DNMT inhibitors and HDAC inhibitors. To date, three DNMT inhibitors are FDA-approved. They are 5-azacitidine, decitabine and Farydak (panobinostat). As for HDAC inhibitors, Vorinostat (SAHA, Zolina), romidepsin (Istodax, FK228, FR901228, depsipeptide) and belinostat (Beleodaq, PXD-101) have been approved for cancer therapy by FDA [39].

So far most epigenetic therapies are studied for cancer. Besides the modifying effect on gene expression, recent studies also show that epigenetic drugs are good immunomodulators. They influence both innate and adaptive immune responses [4]. Many reports have shown that epigenetic drugs are able to improve the costimulatory properties of cancer cells by up regulating surface expression of CD40, CD80, CD86, and ICAM1 and restore their sensitivity to immune cell triggered apoptosis by enhancing the expression of death-inducing receptors [40-42]. Zhang et al., [43] reported that HDAC inhibitors restored function of defective CD8+ T cells from chronic LCMV infection. Archin et al., [44] reported that selective HDAC inhibitors could activate latency HIV infection, which suggests a clinical strategy to target persistent HIV infection. The same group [45] further showed that administration of vorinostat disrupted HIV-1 latency in patients on antiretroviral therapy. This study is of great significance as it indicates that eradication of latent HIV infection is possible. Wei et al. [46] reported that romidepsin could induce HIV expression in CD4 T cells from HIV patients. Recently Tian et al., [47] showed that Telbivudine treatment corrected HBV- induced epigenetic alterations in liver cells of patients with chronic hepatitis B. HBV nuclear cccDNA accumulates in hepatocyte nuclei as a stable minichromosome organized by histone and non-histone viral and cellular proteins [48]. Identification of the molecular mechanisms regulating cccDNA stability and its transcriptional activity at the RNA, DNA and epigenetic levels may reveal new potential therapeutic targets. Taken together, considering the epigenetic regulation of latent HIV and HBV cccDNA, epigenetic therapy may be a promising strategy to conquer chronic/persistent viral infection. Table 2 lists some of the representative studies for epigenetic therapy on chronic viral infections.
studies suggest that combining epigenetic therapy and immunotherapy might be beneficial in treating chronic viral infections. For example, Tropberger et al. [8] found that HBV cccDNA chromatin was modulated by innate immunity and manipulated with an epigenetic agent. Their findings provide rational evidence for treating chronic HBV patients by combining immunotherapy and epigenetic therapy.

One specific goal of epigenetic therapy is to restore normal DNA methylation patterns and to prevent the cells from acquiring further methylation in DNA that could lead to silencing of genes crucial for normal cell function. Concerns appear immediately about epigenetic reagents may have more effects on viral control besides modulating gene expression. One recent report [54] showed that an epigenetic chemical epigallocatechin-3-gallate (EGCG), the main polyphenol compound of green tea, was able to inhibit HCV entry.

The use of decitabine (5-Aza-CdR) has been reported to be selective toward cancer cells, especially those caused by tumor viruses. It is necessary to explore as many as possible molecular mechanisms of epigenetic drugs on cancer and virus infection treatment. As most current epigenetic therapies are focused on cancer patients, it is interesting to check whether the similar recipe will work for patients with chronic viral infection, especially those caused by tumor viruses. It is necessary to explore as many as possible molecular mechanisms of epigenetic drugs on cancer and virus infection treatment. As most current epigenetic therapies are carried out on cancer patients, it is interesting to check whether the similar recipe will work for patients with chronic viral infection.

Finally and most importantly, combining epigenetic therapy together with immunotherapy may provide a promising strategy to break chronic viral infection and induce appropriate immune responses to eradicate viruses from the host.

### Conflicts of Interest

The author declares no conflict of interest.

### Acknowledgement

I highly appreciate one of my previous mentors, Maria Salvato (Institute of Human Virology, University of Maryland, Baltimore), for reading the manuscript and correcting some grammar problem.

### References

1. Sigalotti L, Covre A, Fratta E, Parisi G, Colizzi F, et al. (2010) Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med 8: 56.
2. Maio M, Covre A, Fratta E, Di Giacomo AM, Taverna P, et al. (2015) Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy. Clin Cancer Res 21: 4040-4047.
3. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
4. Sigalotti L, Fratta E, Coral S, Maio M (2014) Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol Ther 142: 339-350.
5. Mair K, Kubicek S, Nijman SM (2014) Exploiting epigenetic vulnerabilities for cancer therapeutics. Trends Pharmacol Sci 35: 136-145.
6. Sarkar S, Horn G, Moulton K, Oza A, Byler S, et al. (2013) Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci 14: 21087-21113.
7. Kumar A, Darcis G, Van Lint C, Herbein G (2015) Epigenetic control of HIV-1 post integration latency: implications for therapy. Clin Epigenetics 7: 103.
8. Tropberger P, Mercier A, Robinson M, Zhong W, Ganem DE, et al. (2015) Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc Natl Acad Sci U S A 112: E5715-5724.
9. El-Ekiaby NM, Mekky RY, El Sobky SA, Elemam NM, El-Sayed M, et al. (2015) Epigenetic harnessing of HCV via modulating the lipid droplet-protein, TIP47, in HCV cell models. FEBS Lett 589: 2266-2273.
10. Kane M, Golovkina T (2010) Common threads in persistent viral infections. J Virol 84: 4116-4123.
11. Virgin HW, Wherry EJ, Ahmed R (2009) Redefining chronic viral infection. Cell 138: 30-50.
12. Moore PS, Chang Y (2010) Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer 10: 878-889.
13. Di Bisceglie AM (2009) Hepatitis B and hepatocellular carcinoma. Hepatology 49: 556-60.
Citation: Jiabin Yan (2016) Epigenetics and Immunotherapy: New Perspective for Breaking Chronic Viral Infection. Immunother Open Acc 2: 106. doi:10.4172/2471-9552.1000106

14. Butel JS (2000) Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 21: 405-426.
15. Hoppe-Seyler F, Hoppe-Seyler K (2011) Emerging topics in human tumor virology. Int J Cancer 129: 1289-1299.
16. Milavetz BI, Balakrishnan L (2015) Viral epigenetics. Methods Mol Biol 1286: 569-596.
17. Ay E, Banati F, Mezei M, Bake A, Niller HH, et al. (2013) Epigenetics of HIV infection: promising research areas and implications for therapy. AIDS Rev 15: 181-188.
18. Okamoto Y, Shinjo K, Shimizu Y, Sano T, Yamao K, et al. (2014) Hepatitis virus infection affects DNA methylation in mice with humanized livers. Gastroenterology 146: 562-572.
19. Lusie M, Marcello A, Cereseto A, Giaccu M (2003) Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J 22: 6550-6561.
20. Johannsen E, Lambert PF (2013) Epigenetics of human papillomaviruses. Virology 445: 205-212.
21. Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki Y, et al. (2009) Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 69: 2766-2774.
22. Laursen J, Khan S, Chung R, Cross K, Raj K (2010) Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. Carcinogenesis 31: 918-926.
23. Rincon-Orozco B, Halec G, Rosenberger S, Muschik D, Nindl I, et al. (2014) Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaque. J Virol 88: 3329-3339.
24. Nonjappa SG, Kim EH, Suresh M (2011) Immunotherapeutic effects of IL-7 during a chronic viral infection in mice. Blood 117: 5123-5132.
25. Salem ML, El-Badawy A (2015) Programmed death-1/programmed death-1 ligand signaling pathway and blockade in hepatitis B virus immune therapy. World J Hepatol 7: 2449-2458.
26. Fisher AK, Voronin Y, Jefferys R (2014) Therapeutic HIV vaccines: prior setbacks, current advances, and future prospects. Vaccine 32: 5540-5545.
27. Pennala-MacMaster P, Kamphorst AO, Wieland A, Araki K, Iyer SS, et al. (2014) Interplay between regulatory T cells and CD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med 211: 1905-1918.
28. Caskey M, Klein F, Lorenzo JC, Seaman MS, West AP Jr, et al. (2015) Viral immunity suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522: 487-491.
cancer epigenome revealed by a multimodality approach. Cancer Cell 6:
361-371.